LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50
Benzinga Newsdesk 2 months ago
NewsInitiationAnalyst RatingsPrice Target
LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating and announces Price Target of $50.
LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating and announces Price Target of $50.